Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 4/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | COMT | P21964 | 1/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | TNKS | O95271 | 2/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.38 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23736196 | 0.78 | SCN2A (0.59) | SCN2ATRPV1COMTNPY5RGFER | |
| SCHEMBL25579108 | 0.78 | SCN2A (0.55) | SCN2ANPY5RDGAT1KDM1A | |
| SCHEMBL15331905 | 0.71 | COMT (0.57) | SCN2ATRPV1COMTNPY5RGFER | |
| SCHEMBL5833712 | 0.71 | COMT (0.65) | SCN2ATRPV1COMTNPY5RRAB9A | |
| SCHEMBL2433653 | 0.70 | COMT (1.00) | SCN2ATRPV1COMTNPY5RTNKS | |
| SCHEMBL26625383 | 0.70 | SCN2A (0.69) | SCN2ATRPV1COMTNPY5RDGAT1 | |
| SCHEMBL7012072 | 0.70 | RECQL (0.67) | SCN2ATRPV1COMTNPY5RRAB9A | |
| SCHEMBL12740574 | 0.70 | HTT (0.33) | KDM4EPOLBKDM1A | |
| SCHEMBL2609357 | 0.68 | KIF11 (0.47) | SCN2AKDM4EKDM5BKIF11NPBWR1 | |
| SCHEMBL30406459 | 0.67 | SCN2A (0.60) | SCN2ATRPV1COMTNPY5RRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-31 | — | — | US | disclosed |
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | SCN2A 1341/4885TRPV1 631/4885COMT 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.